Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0036341 (
schizophrenia
)
60,220
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
To study the change of gene expression in the brain tissues of
schizophrenia
, we used the gene expression monitoring technology and compared two sets of pools each containing four RNA samples of frontal cortex that were randomly selected from the control or
schizophrenia
group. We found that the expression of two genes were commonly altered in four pairwise comparisons; the expression of
DEAD-box protein p72
(p72) gene was increased and neuropeptide Y (NPY) gene expression was decreased in the
schizophrenia
group compared with the control group. To substantiate these results, we estimated their mRNA levels by the real time TaqMan method in the 15 samples of each frontal or temporal cortex of four matched groups of
schizophrenia
, bipolar disorder, major depression and normal controls. A statistically significant decrease was observed for NPY in the frontal, but not in the temporal cortex, in the
schizophrenia
group (P=0.003). A decrease was also observed in the frontal cortex of the bipolar disorder group (P=0.031). In contrast, p72 gene expression showed no significant difference among the four groups. In conclusion, by novel technology of DNA array and TaqMan PCR analyses, we found that neuropeptide Y mRNA levels were significantly reduced in the frontal cortex in both
schizophrenia
and bipolar disorder.
...
PMID:Reduced neuropeptide Y mRNA levels in the frontal cortex of people with schizophrenia and bipolar disorder. 1501 14
